C-Peptide Test Explained
What C-peptide measures, why it separates Type 1 from Type 2 diabetes better than insulin does, and what a high or low result means for unexplained low blood sugar.
Free to use, no credit card, works with any Australian lab
· · Reviewed against the sources listed at the end of this page.
The Quick Answer
C-peptide (short for connecting peptide) is a small protein fragment that the pancreas snips off a larger molecule called proinsulin, releasing it into the blood in equal, one-for-one amounts alongside insulin, every single time a beta cell secretes insulin. Measuring C-peptide is, in effect, a way of measuring how much insulin your own pancreas is producing right now.
The key advantage over measuring insulin directly: injected insulin, the kind used to treat diabetes, contains no C-peptide at all, so C-peptide keeps working as a true measure of the pancreas's own output even in someone already using insulin therapy. It also has a longer half-life than insulin, and unlike insulin it is not stripped out by the liver on its first pass through the bloodstream, which makes it a more stable and reliable number to test.
C-peptide is only useful next to a glucose result taken at the same time. A low C-peptide when glucose is also low can be entirely normal. The same low C-peptide at a normal or high glucose is abnormal. This pairing is the single most important rule on this page.
Typical adult reference range quoted by Australian pathology laboratories (fasting):
C-peptide does not have one nationally harmonised reference interval the way electrolytes or a full blood count do, and the exact range depends on the laboratory and assay used. Always check the range printed on your own pathology report rather than a figure quoted elsewhere.
What C-Peptide Actually Measures
Inside the beta cells of the pancreas, insulin is first made as a single, longer molecule called proinsulin. Before it is released, an enzyme cuts proinsulin into two pieces: the insulin molecule itself, and the leftover connecting fragment, C-peptide. Both pieces are stored together and released into the bloodstream together, in a fixed one-to-one ratio, whenever the pancreas secretes insulin.
Why C-peptide reflects pancreatic output better than measuring insulin
Three properties of C-peptide make it the preferred marker of the pancreas's own insulin output, rather than simply measuring insulin itself.
Injected insulin contains no C-peptide
Commercial insulin products used to treat diabetes are manufactured without any C-peptide attached. That means a measured C-peptide level always reflects the person's own pancreas, never the insulin they have injected, which is exactly why C-peptide keeps working as a test in people already on insulin therapy, when measuring insulin itself no longer tells you anything useful.
A longer half-life in the blood
Insulin is cleared from the blood within a few minutes of release. C-peptide lingers for considerably longer, roughly 20 to 30 minutes. This makes C-peptide a steadier, less minute-to-minute number, less prone to being caught mid-spike or mid-trough by the exact moment the blood is drawn.
Not stripped out by the liver on its first pass
After release from the pancreas, insulin travels straight to the liver, which removes roughly half of it before it ever reaches the rest of the body. C-peptide passes through the liver largely untouched and is cleared mainly by the kidneys instead. This means a measured insulin level understates true pancreatic output, while C-peptide reflects it far more directly.
The Main Clinical Uses of C-Peptide
C-peptide is a specific-purpose test. It is rarely ordered as part of a routine check-up, and is almost always requested to answer one of the questions below.
Distinguishing Type 1 from Type 2 diabetes
A low or undetectable C-peptide supports Type 1 diabetes (an absolute lack of insulin). A preserved or high C-peptide supports Type 2 diabetes, which usually starts as insulin resistance with the pancreas still producing, or even overproducing, insulin.
Most useful once the diagnosis is at least a few years old. Soon after a Type 1 diagnosis, a temporary honeymoon period can leave measurable insulin production for months, sometimes longer, which can make the test misleading if done too early.
Clarifying MODY versus Type 1 diabetes
Maturity onset diabetes of the young, a group of inherited single-gene conditions, usually preserves C-peptide production for years despite a young age at diagnosis, unlike Type 1 diabetes where C-peptide falls early.
A preserved C-peptide in someone diagnosed with diabetes under the age of 25, without insulin at diagnosis and without positive islet autoantibodies, should prompt consideration of MODY and referral for genetic testing.
Checking residual beta cell function on insulin therapy
In someone already using insulin, C-peptide (checked with a matching glucose, ideally away from a recent hypo) shows whether the pancreas is still contributing any of its own insulin alongside the injected dose.
A preserved C-peptide in a person on insulin can support a Type 2 rather than Type 1 diagnosis retrospectively, and can influence whether other diabetes medicines are worth adding alongside insulin.
Investigating unexplained low blood sugar
C-peptide, measured at the time of a genuinely low glucose, separates hypoglycaemia driven by the person's own pancreas (insulinoma, sulfonylurea use) from hypoglycaemia driven by outside insulin or by a non-insulin cause entirely.
See the glucose and C-peptide pattern table further down this page. This is one of the most clinically important uses of the test.
Assessing residual function in long-standing Type 1 diabetes
Even decades after diagnosis, a minority of people with Type 1 diabetes retain a small but measurable C-peptide, and this is associated with more stable glucose control and fewer severe hypoglycaemic episodes.
Mostly checked in a research context, for example in trials of therapies aiming to preserve remaining beta cell function, though some endocrinologists now check it clinically in people with unusually stable long-term control.
Already had your C-peptide, glucose, or insulin tested?
Upload your pathology PDF and SmarterBlood explains what your specific C-peptide, glucose, and insulin combination points to, in plain English, alongside every other marker on your report.
Upload Your Results FreeThree Rules for Reading a C-Peptide Result
Rule 1: A low C-peptide only means something if glucose is not also low
A healthy pancreas is supposed to switch insulin production down when blood sugar falls. A low C-peptide at a low glucose can therefore be the correct, expected response, not a problem. The same low C-peptide result at a normal or high glucose is a very different and clinically significant finding, since insulin output should be rising, not falling, at that glucose level. Reading C-peptide without its matching glucose is one of the most common ways this test gets misinterpreted.
Rule 2: Chronic kidney disease raises C-peptide, independent of the pancreas
The kidneys are a major route by which C-peptide is removed from the blood, more so than insulin. When kidney function declines, C-peptide clears more slowly and accumulates, so results can look artificially high or reassuring in someone with reduced eGFR, even though their pancreas is not making any more insulin than before. Your GP or endocrinologist needs your kidney function alongside the C-peptide to interpret the number properly.
Rule 3: Random, fasting, and stimulated testing answer different questions
A random, non-fasting C-peptide taken at the time of a symptomatic low blood sugar is often the most useful sample for investigating hypoglycaemia, because it captures what the pancreas was doing at exactly the wrong moment. For clarifying diabetes type, a fasting sample is more standard. For assessing how much reserve capacity the pancreas has left, an endocrinologist may instead request a stimulation test, such as a glucagon stimulation test or a mixed-meal tolerance test, where C-peptide is measured before and after a controlled stimulus rather than as a single snapshot.
Interpreting Glucose, C-Peptide, and Insulin Together
When investigating unexplained low blood sugar, the combination of glucose, C-peptide, and insulin, taken from the same sample at the time of the low reading, is far more informative than any one value on its own. This is the single most useful pattern on this page.
Low glucose + High C-peptide + High insulin
The pancreas itself is releasing too much insulin at the wrong time
Likely cause: Endogenous hyperinsulinism: an insulinoma (a rare insulin-producing pancreatic tumour) or a sulfonylurea/glinide medicine. A blood or urine sulfonylurea screen, alongside pancreatic imaging, is needed to tell the two apart.
Low glucose + Low C-peptide + High insulin
Measured insulin is high but it is not coming from the person's own pancreas
Likely cause: Exogenous insulin, meaning insulin given from outside the body. The injected insulin suppresses the pancreas's own C-peptide output, which is exactly why the two results split apart. Seen in accidental, deliberate, or factitious insulin use.
Low glucose + Low C-peptide + Low or normal insulin
Low blood sugar that is not being driven by insulin at all
Likely cause: Non-insulin-mediated hypoglycaemia: severe liver disease, adrenal insufficiency (cortisol deficiency), sepsis, a large non-islet cell tumour, or reactive hypoglycaemia after gastric surgery.
Normal or high glucose + Low C-peptide
The pancreas is not producing enough insulin for the glucose level in front of it
Likely cause: Type 1 diabetes, particularly with positive islet autoantibodies. Also seen in long-standing Type 2 diabetes once beta cell reserve has been exhausted, and after pancreatic surgery or severe pancreatitis.
Normal or high glucose + Normal or high C-peptide
The pancreas is producing a reasonable, or excessive, amount of insulin for the glucose level
Likely cause: Type 2 diabetes or prediabetes with insulin resistance (the pancreas is working hard to compensate), MODY, or metabolic syndrome. Occasionally an early insulinoma if hypoglycaemic symptoms are also present intermittently.
Type 1, Type 2, MODY, and LADA Side by Side
No single test confirms the type of diabetes on its own. C-peptide, age at onset, family history, and islet autoantibody results are read together, and this is usually done with an endocrinologist involved when the picture is not straightforward.
Type 1 diabetes
Typical C-peptide: Low or undetectable, especially years after diagnosis
Typical onset: Any age, often (not always) children, teenagers, or young adults
Islet autoantibodies: Usually positive: GAD65, IA-2, ZnT8, or islet cell antibodies
Autoimmune destruction of insulin-producing beta cells leads to an absolute insulin deficiency. Insulin treatment is required for life.
Type 2 diabetes
Typical C-peptide: Normal to high early on, reflecting insulin resistance; can fall after many years
Typical onset: Usually adults, often with overweight, a strong family history, or metabolic syndrome
Islet autoantibodies: Usually negative
Starts as insulin resistance with the pancreas compensating by making more insulin. Beta cell output can decline gradually over decades.
MODY
Typical C-peptide: Preserved, often within the normal range, for years after diagnosis
Typical onset: Usually diagnosed before age 25, with diabetes in multiple generations of the family
Islet autoantibodies: Negative
A group of single-gene disorders affecting beta cell function. Some subtypes respond well to sulfonylurea tablets rather than insulin, so getting the diagnosis right matters.
LADA (latent autoimmune diabetes in adults)
Typical C-peptide: Intermediate at diagnosis, then declining over months to a few years
Typical onset: Adult onset, often in the 30s to 50s, initially resembling Type 2 diabetes
Islet autoantibodies: Usually positive, most often GAD65
A slowly progressive autoimmune process. People with LADA often need insulin sooner than a typical Type 2 diagnosis would predict.
Want to see how C-peptide fits with glucose, insulin, and HOMA-IR?
Read the Glucose and Insulin Markers GuideGetting Tested in Australia and Medicare
C-peptide is available at all major Australian pathology providers and uses a standard blood draw, generally taken at the same time as glucose and, where relevant, insulin. It is not one of the tests usually ordered as part of a routine annual check, and it is usually ordered by, or after discussion with, a GP or endocrinologist for one of the specific reasons described above rather than as a general screening test.
A Medicare rebate can apply, but the pathology rules covering hormone assays like this one typically require the test to be requested by, or on the advice of, a specialist, usually an endocrinologist, for a defined clinical reason such as investigating hypoglycaemia or clarifying an atypical diabetes presentation. A request made outside those criteria, for example a routine GP request with no specific indication, may not attract a rebate.
Where no rebate applies, Australian pathology providers will generally still perform the test as a private, out-of-pocket request for a modest fee. Ask your GP or endocrinologist whether your specific reason for testing is likely to meet the rebate criteria before the sample is collected, since this varies by clinical scenario and is reviewed periodically.
What Your GP or Endocrinologist Does Next
Order C-peptide with a simultaneous glucose
Your GP or endocrinologist will request C-peptide alongside a glucose from the same blood draw, and very often an insulin level too. Without the matching glucose, the C-peptide result on its own cannot be interpreted safely.
Decide between random, fasting, or stimulated testing
A random (non-fasting) sample taken at a symptomatic moment is often the most useful for suspected hypoglycaemia. For diabetes-type clarification, a fasting or paired glucagon stimulation or mixed-meal test may be requested instead, particularly by an endocrinologist.
Check kidney function alongside the result
Because reduced kidney function raises C-peptide by slowing its clearance, your eGFR is checked at the same time so the result is not read at face value in someone with chronic kidney disease.
Add islet autoantibodies if Type 1 versus Type 2 is unclear
GAD65, IA-2, ZnT8, and islet cell antibodies are usually checked alongside C-peptide when the diabetes type is genuinely uncertain, since the antibody pattern and the C-peptide result answer different but complementary questions.
Arrange a supervised fast or imaging if an insulinoma is suspected
When hypoglycaemia with a high C-peptide is not explained by a sulfonylurea, a supervised prolonged fast (traditionally 72 hours, done in hospital) and pancreatic imaging (CT, MRI, or endoscopic ultrasound) are the standard next steps, arranged through an endocrinologist.
Review medicines that can affect the result or cause hypoglycaemia
Sulfonylureas, glinides, and insulin itself are the main medicine-related causes of a confusing C-peptide and glucose picture. Bring a full, accurate list of everything you take, including anything borrowed or bought without a prescription.
Refer to an endocrinologist for anything outside a routine pattern
Genuinely unclear diabetes typing, recurrent unexplained hypoglycaemia, or a suspected insulinoma are all specialist-level problems. Your GP will usually refer rather than manage these independently.
When to Seek Urgent Care
Confusion, slurred speech, or difficulty concentrating during a low blood sugar episode
These are signs the brain is being starved of glucose. If you or someone with you cannot safely eat or drink something sugary, call 000.
Loss of consciousness or a seizure with a known or suspected low glucose
This is a medical emergency. Call 000 immediately and follow the instructions the operator gives you. Australian first aid guidance covers the use of a prescribed glucagon injection kit by someone trained in it, and the ambulance operator will talk a bystander through what to do while help is on the way.
Repeated unexplained low blood sugar episodes, especially without diabetes medication
Recurrent hypoglycaemia in someone not on insulin or sulfonylureas needs prompt medical review to investigate causes such as an insulinoma. Keep a diary of timing, symptoms, and what you ate beforehand.
Low blood sugar with a very high measured insulin but a low C-peptide
This pattern points towards exogenous insulin and needs a timely, sometimes urgent, specialist assessment rather than routine follow-up.
Tingling, numbness, or unsteady balance alongside longstanding unexplained hypoglycaemia
Prolonged or recurrent severe hypoglycaemia can affect the nervous system. Do not wait for these symptoms to resolve on their own; see your GP promptly.
Sources and reference ranges
Adult reference ranges on this page follow the AACB and RCPA harmonised reference intervals unless stated otherwise; the range printed on your own report always takes precedence because laboratories differ.
C-Peptide Test Explained, Frequently Asked Questions
What is a C-peptide test and why would my doctor order it?
A C-peptide test measures a small protein fragment that your pancreas releases in equal amounts to insulin, every time it makes insulin. Because it is released one for one with your own insulin, but is not present in any injected insulin product, it works as a direct measure of how much insulin your pancreas is still making. GPs and endocrinologists order it mainly to help tell Type 1 from Type 2 diabetes when the picture is unclear, to check whether someone already on insulin still has working beta cells, and to investigate unexplained low blood sugar.
What is a normal C-peptide level in Australia?
Australian pathology laboratories typically quote a fasting adult reference interval of roughly 0.3 to 1.3 nmol/L, though the exact range depends on the laboratory and the assay used, since C-peptide does not have one nationally harmonised range the way electrolytes or a full blood count does. Always read the range printed on your own report rather than a number from the internet. A result is only meaningful when read alongside the glucose taken from the same blood draw, since a normal C-peptide at a low glucose is a very different result to the same C-peptide at a high glucose.
Can C-peptide tell the difference between Type 1 and Type 2 diabetes?
It is one of the more useful tools for this, particularly a few years after diagnosis. A low or undetectable C-peptide, especially with positive islet autoantibodies such as GAD or IA-2, supports Type 1 diabetes. A preserved or high C-peptide supports Type 2 diabetes, since Type 2 usually starts with insulin resistance rather than an absolute lack of insulin. It is less reliable in the first months after a Type 1 diagnosis, when a temporary honeymoon period can leave some insulin production intact, and it does not replace autoantibody testing or clinical judgement.
Why do I need a glucose test at the same time as C-peptide?
C-peptide only makes sense next to a simultaneous glucose. Your pancreas is supposed to turn insulin production down when blood sugar is low, so a low C-peptide at a low glucose can be entirely normal and appropriate. The same low C-peptide result at a normal or high glucose is abnormal, because insulin production should be higher, not lower, at that glucose level. A C-peptide result without a matching glucose from the same sample is difficult to interpret safely, which is why labs and specialists insist on pairing the two.
Does kidney disease affect C-peptide results?
Yes. The kidneys are a major route by which C-peptide is cleared from the blood, considerably more so than insulin. In chronic kidney disease, clearance slows down and C-peptide levels rise even though the pancreas is not making any more insulin than before. This means a C-peptide result in someone with reduced kidney function can look artificially high or reassuring, and your GP or endocrinologist needs to know your kidney function (eGFR) to interpret the result correctly.
What does a low C-peptide with low blood sugar mean?
A low C-peptide at a low glucose usually means the low blood sugar is not being driven by the person's own pancreas. The most common explanation is exogenous insulin, meaning insulin has been injected from outside the body, which suppresses the pancreas's own C-peptide production while the measured insulin level (from the injection) can still be high. Other causes of low glucose with low C-peptide include liver failure, adrenal insufficiency, sepsis, and some non-islet cell tumours. This combination is usually investigated urgently.
What does a high C-peptide with low blood sugar mean?
A high or inappropriately normal C-peptide at a low glucose points to the pancreas itself producing too much insulin at the wrong time, a pattern doctors call endogenous hyperinsulinism. The two leading causes are an insulinoma, a rare insulin-producing tumour of the pancreas, and sulfonylurea medicines, a class of diabetes tablets that stimulate the pancreas to release more insulin. Distinguishing the two usually needs a blood or urine sulfonylurea screen alongside imaging of the pancreas, and is generally managed by an endocrinologist.
Is the C-peptide test covered by Medicare in Australia?
A Medicare rebate can apply, but the pathology rules for hormone assays like this one usually require the test to be requested by, or on the advice of, a specialist such as an endocrinologist, for a specific clinical reason such as investigating hypoglycaemia or clarifying an atypical diabetes diagnosis. A routine GP request outside those criteria may not attract a rebate. Where no rebate applies, most Australian pathology providers still perform the test privately for a modest out-of-pocket fee. Ask your GP or endocrinologist whether your reason for testing is likely to qualify before the sample is collected.
What is a C-peptide stimulation test?
A single fasting or random C-peptide gives a snapshot, but a stimulation test shows how much reserve capacity the pancreas still has. The two used in Australian practice are a mixed-meal tolerance test, where C-peptide is measured before and after a standard test drink, and a glucagon stimulation test, where C-peptide is measured before and shortly after an injection of glucagon. Both are used mainly in specialist and research settings, for example to gauge residual beta cell function in recently diagnosed Type 1 diabetes, and are less commonly needed in routine general practice.
Related Reading
Got a C-Peptide, Glucose, or Insulin Result?
Upload your pathology PDF and SmarterBlood's AI explains C-peptide, glucose, insulin, and HbA1c together in plain English, with Australian reference ranges, so you understand what your results mean before your next appointment.
This page provides general educational information about the C-peptide blood test and how it is used to investigate diabetes type and unexplained low blood sugar. It is not a substitute for professional medical advice, diagnosis, or treatment, and it does not diagnose any condition. Always discuss your own C-peptide, glucose, and insulin results with your GP or endocrinologist, who can interpret them in the context of your full medical history. SmarterBlood does not provide medical care.